AstraZeneca Pharmaceuticals LP has sued Osmotica Pharmaceutical Corp., marking the drug giant's latest effort to stop a rival from coming out with a generic version of schizophrenia treatment Seroquel XR®. Osmotica's version of the drug would infringe a patent held by AstraZeneca, according to a complaint filed Monday in the U.S. District Court for the Eastern District of North Carolina. Osmotica filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration seeking to market a generic version of Seroquel XR® before U.S. Patent Number 5,948,437 expires in 2017, the complaint alleges. The ‘437 patent covers the release of formulations of Seroquel XR's® active ingredient, known as quetiapine fumarate, and the processes for preparing and using those formulations. AstraZeneca is represented by Finnegan.
Commentary
April 11, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Press Release
February 13, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.